Business context and reporting period
Filing identity: The supplied filing is Access Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended September 30, 2013, filed November 14, 2013. This does not match the request metadata naming Abeona Therapeutics Inc.; verify the issuer before relying on this summary.
Access described itself as an emerging biopharmaceutical company focused on drug-delivery technologies. Its marketed product was MuGard for oral mucositis; other programs included Phase 2 ProLindac and preclinical platforms. Financial statements are unaudited.
Financial results and liquidity
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Total revenue | $189,000 | $871,000 | $1.880 million | $3.398 million |
| Operating expenses | $885,000 | $1.827 million | $5.000 million | $6.495 million |
| Loss from operations | $696,000 | $956,000 | $3.120 million | $3.097 million |
| Net income (loss) | $(157,000) | $(14.867) million | $5.524 million | $(30.359) million |
| Net income (loss) allocable to common stockholders | $(899,000) | $(15.311) million | $3.322 million | $(31.682) million |
| Basic and diluted EPS | $(0.04) | $(0.63) | $0.13 | $(1.31) |
- Nine-month 2013 income included an $8.471 million gain from remeasurement of the preferred-stock derivative liability; the large year-over-year earnings swing therefore does not reflect operating profitability. The company reported a $3.120 million operating loss for the period.
- Nine-month revenue fell 45% year over year. MuGard U.S. product sales were $1.542 million through the June 6 license transfer, versus $1.950 million in the prior-year period. Q3 product sales were zero after the transfer; Q3 U.S. royalties were $45,000.
- Cash and cash equivalents were $899,000 at September 30, 2013, compared with $396,000 at December 31, 2012. Working capital deficit was $6.966 million, up from $4.948 million at year-end. Total assets were $1.092 million and total liabilities $14.256 million.
- Operating cash flow was positive $475,000 for the first nine months, versus cash used of $2.339 million in 2012. Cash flow included a $3.010 million increase in deferred revenue and working-capital movements; it should not be read as evidence of sustainable operating cash generation. Investing cash outflow was $1,000 and financing inflow was $29,000.
- Preferred dividends of $2.202 million were accrued in the nine-month period; total dividends payable were $5.870 million at September 30. The filing reports no separate debt balance on the balance sheet and says the $2.75 million secured promissory note was paid off in November 2012. Gross margin is not clearly stated.
Material changes versus the prior comparable period
- MuGard’s U.S. commercialization shifted to AMAG under an exclusive license dated June 6, 2013. Access received a $3.3 million upfront fee, recorded as deferred revenue and recognized over the ten-year license term, plus tiered double-digit royalties. AMAG also purchased existing inventory and bears product costs after the transfer.
- Nine-month R&D expense declined to $756,000 from $1.712 million, primarily reflecting reduced staffing, completed or reduced clinical work, and laboratory closure. Nine-month SG&A declined to $4.117 million from $4.491 million, despite higher legal and consulting costs.
- 2013 nine-month results compare with a 2012 period that included a $25.770 million preferred-derivative loss and $2.316 million warrant-extension expense. The derivative gains and losses are valuation-driven and can cause substantial reported earnings volatility.
- Cash increased, but receivables fell to $56,000 from $840,000 and inventory to zero from $194,000; the filing attributes the transfer of MuGard inventory and receivables in part to the AMAG arrangement.
Outlook, risks, contingencies, and unusual items
- Management expected cash, MuGard royalties, and license-related receipts to fund the then-current operating level only into the first quarter of 2014. It stated that additional funds would be required and warned that failure to obtain financing or licensing receipts could threaten continued operations and going-concern status. The prior-year audit report included a going-concern explanatory paragraph.
- The company expected losses for several years and could not assure sustained profitability. It said it lacked sufficient capital as of November 14, 2013 to achieve long-term goals.
- Series A preferred stock carries a 6% dividend rate and Series B a 12% rate; dividends may be payable in cash or shares subject to specified conditions. The filing also reports $857,000 accrued in liquidated damages related to an outstanding registration obligation.
- A material weakness in internal control over financial reporting remained unremediated, arising from limited accounting staff and lack of segregation of duties in financial reporting. Management said disclosure controls were not effective, while noting no known effect on current-period financial-statement accuracy.
- A former Genaera shareholder’s claims against the company and related defendants were dismissed in August 2013, but the plaintiff appealed; the company said it would contest the claims. No other material pending legal proceedings were reported.
Important facts for investors to verify
- Confirm the issuer: the filing identifies Access Pharmaceuticals, not Abeona Therapeutics.
- Check subsequent filings for actual cash runway, financing, royalty receipts, and whether the Q1 2014 funding expectation was met.
- Assess the terms, accrued dividends, conversion rights, and potential dilution from Series A and Series B preferred stock; the filing lists substantial preferred-stock and warrant conversion shares.
- Evaluate the quality of reported nine-month income by separating noncash derivative remeasurement gains from operating performance and cash generation.
- Review remediation of the disclosed material weakness, the registration-related liquidated damages, and the status of the appeal in the Genaera litigation.